Dr Maxwell has been instrumental in the development and evolution of many of the principles, operative techniques, and medical devices which compose the current global practice of aesthetic and reconstructive breast surgery. Serving as Clinical Professor of Plastic Surgery at both Vanderbilt University in Nashville, Tennessee, and Loma Linda University in Southern California, his passion for innovation as well as education, has been influential in the developmental careers of his former plastic surgery residents , personal fellows, as well as his peers, for almost four decades.
While a resident in plastic surgery at the Johns Hopkins Hospital, Baltimore, MD., Dr Maxwell, having completed a microsurgery fellowship with Dr Harry Buncke, performed and reported the world’s first Latissimus Dorsi free flap. Moving from microsurgery to breast surgery, and after pioneering techniques Latissimus and TRAM flaps, Dr Maxwell focused on implant-based breast reconstruction. He invented the first surface- altered tissue expander which enabled him (working with McGhan Medical/ Inamed / Allergan) to design/develop the first anatomical shaped expander and a “made to match” anatomical shaped silicone gel implant. Concomitantly he developed the clinical system for use of these devices, based on dimensions rather than volume, with the breast base width measurement as the keystone. This was commercialized as the BioDimensional System of devices (and technique), later termed the “Natrelle Breast Reconstruction System”(by Allergan) consisting of the Style 133 matrix of tissue expanders, and the 410 matrix anatomical-shaped cohesive gel implants, as well as the Inspira matrix of round cohesive gel implants. He founded and chaired the Inamed/Allergan Academies focused on educating surgeons around the world.
Additionally Dr Maxwell (with Medical Device Alliance, now Mentor Corp) developed their ultrasonic liposuction technology/platform . He co-founded Precision Light (a 3-D imaging technology) acquired by Allergan and incorporated into the Vectra XT Technology. He is a founder, principle in GID (an adipose/adipose-derived stem cell company) whose products include Revolve (an adipose processing system for fat grafting) and an adipose stem cell platform in phase 3 FDA clinical trials for treatment of osteoarthritic knee pain. He is a founder and former board member of Alphaeon, whose Evolus company markets the neurotoxin Jeveau, the the US.
Dr. Maxwell has published more than 150 scientific articles, co-authored several books, and has performed live surgical demonstrations in more than twenty countries worldwide. He holds twenty U.S. patents for medical devices as well as multiple international patents. He co-edited the recently introduced, “Spear’s Surgery of the Breast : Principles and Art, Fourth Edition.
Dr. Maxwell has been honored with most of the awards bestowed in plastic surgery. He is the recipient of the “Clinician of the Year Award” and the “James Barrett Brown Award” from the American Association of Plastic Surgeons, the “Robert Ivey Award “ and the “Presidential Award” from the American Society of Plastic Surgeons; the “Simon Fredrick Award”, the “Chula Song Award”, and the “Walter Scott Brown” (x3), and Journalistic Award for Best Scientific Paper published in ASJ for the year 2011, and the best video-paper in 2018 (ASJ), all from the American Society for Aesthetic Plastic Surgery,.
In 2007, he received the U.S. Congressional Recognition of Merit for “his visionary contributions to plastic and reconstructive surgery, service to others, and revolutionary developments impacting survivor of breast cancer”.